Meet
Kylie Stengel

Kylie Stengel supports clients spanning a range of healthcare sectors and stakeholders in assessing the impacts of the evolving policy landscape on their business and advocacy priorities.

She focuses on regulatory and legislative developments, with specific expertise in Medicare Part D payment and policy, drug pricing reforms, and health insurance markets.

Kylie has previous experience in the MedStar Georgetown Transplant Institute, where she helped lead a process improvement plan to enhance operating efficiency and patient experience. Additionally, she has experience with the Marwood Group, where she supported the life sciences team to synthesize research and deliver industry analysis, including surveying the regulatory and legislative outlook for pharmaceutical and biotechnology companies.

Kylie has a BS in healthcare management policy from Georgetown University’s School of Nursing and Health Studies.

Authored Content


Scenario analysis of varying levels of negotiation under H.R.3 (as released on September 19) finds that the bill could reduce federal spending by $790B to $1,055B and decrease manufacturer revenues by $1,125B to $1,520B for CY 2020–2029.

As policymakers consider reforms to the Part D benefit to address rising out-of-pocket (OOP) costs by adding a maximum OOP cap, an Avalere analysis examines the types of beneficiaries mostly likely to be helped by such a policy.

Avalere analysis finds that a larger proportion of beneficiaries taking a Part D cancer therapy reached catastrophic compared to all Part D enrollees.

As policymakers increasingly consider policy options to reform Medicare Part D and reduce program expenditures, an Avalere analysis examines spending across classes with various availability of brand and generic drugs.